Recent advances in metabolic and bariatric surgery.

F1000Research

Volumn 5, Issue , 2016, Pages

  Albaugh, Vance L ^a   Flynn, C Robb ^a   Tamboli, Robyn A ^a   Abumrad, Naji N ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLESTYRAMINE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY; PROTEIN TYROSINE PHOSPHATASE SHP; TGR5 RECEPTOR; UNCLASSIFIED DRUG;

BILE DIVERSION; BILIARY TRACT SURGERY; BILIOPANCREATIC BYPASS; COMORBIDITY; DIET INDUCED OBESITY; ENDOPLASMIC RETICULUM STRESS; FOOD INTAKE; GASTRIC BANDING; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; ILEAL INTERPOSITION; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE ANASTOMOSIS; INTESTINE FLORA; LIPID METABOLISM; MALABSORPTION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; ROUX-EN-Y GASTRIC BYPASS; SIGNAL TRANSDUCTION; SLEEVE GASTRECTOMY; STOMACH TUBE; WEIGHT REDUCTION;

EID: 85010917053     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.7240.1     Document Type: Review

References (150)

1. Blackburn G: Effect of degree of weight loss on health benefits. Obes Res. 1995; 3(Suppl 2): 211s-216s.
2. Look AHEAD Research Group: Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014; 22(1): 5-13.
3. Wing RR, Lang W, Wadden TA, et al.: Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34(7): 1481-6.
4. Schauer PR, Bhatt DL, Kirwan JP, et al.: Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 2014; 370(21): 2002-13.
5. Schauer PR, Kashyap SR, Wolski K, et al.: Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012; 366(17): 1567-76.
6. Courcoulas AP, Goodpaster BH, Eagleton JK, et al.: Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg. 2014; 149(7): 707-15.
7. Courcoulas AP, Christian NJ, O'Rourke RW, et al.: Preoperative factors and 3-year weight change in the Longitudinal Assessment of Bariatric Surgery (LABS) consortium. Surg Obes Relat Dis. 2015; 11(5): 1109-18.
8. Pories WJ, Swanson MS, MacDonald KG, et al.: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995; 222(3): 339-50; discussion 350-2.
9. Wickremesekera K, Miller G, Naotunne TD, et al.: Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005; 15(4): 474-81.
10. Jørgensen NB, Jacobsen SH, Dirksen C, et al.: Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab. 2012; 303(1): E122-31.
11. Ackerman NB: Observations on the improvements in carbohydrate metabolism in diabetic and other morbidly obese patients after jejunoileal bypass. Surg Gynecol Obstet. 1981; 152(5): 581-6.
12. Buchwald H, Avidor Y, Braunwald E, et al.: Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292(14): 1724-37.
13. Sjöström L, Lindroos AK, Peltonen M, et al.: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351(26): 2683-93.
14. Sugerman HJ, Wolfe LG, Sica DA, et al.: Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003; 237(6): 751-6; discussion 757-8.
15. Scopinaro N, Papadia F, Marinari G, et al.: Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/m2. Obes Surg. 2007; 17(2): 185-92.
16. Fried M, Ribaric G, Buchwald JN, et al.: Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies. Obes Surg. 2010; 20(6): 776-90.
17. Scopinaro N, Adami GF, Papadia FS, et al.: Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg. 2011; 253(4): 699-703.
18. Scopinaro N, Adami GF, Papadia FS, et al.: The effects of biliopancreatic diversion on type 2 diabetes mellitus in patients with mild obesity (BMI 30-35 kg/m2) and simple overweight (BMI 25-30 kg/m2): a prospective controlled study. Obes Surg. 2011; 21(7): 880-8.
19. Scopinaro N, Adami GF, Papadia FS, et al.: Effects of gastric bypass on type 2 diabetes in patients with BMI 30 to 35. Obes Surg. 2014; 24(7): 1036-43.
20. Adams TD, Davidson LE, Litwin SE, et al.: Health benefits of gastric bypass surgery after 6 years. JAMA. 2012; 308(11): 1122-31.
21. Adams TD, Gress RE, Smith SC, et al.: Long-term mortality after gastric bypass surgery. N Engl J Med. 2007; 357(8): 753-61.
22. Borisenko O, Adam D, Funch-Jensen P, et al.: Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. Obes Surg. 2015; 25(9): 1559-68.
23. Dimick JB: Does Bariatric Surgery Reduce Health Care Costs?: Weighing the Evidence. JAMA Surg. 2015; 150(8): 795.
24. Lewis KH, Zhang F, Arterburn DE, et al.: Comparing Medical Costs and Use After Laparoscopic Adjustable Gastric Banding and Roux-en-Y Gastric Bypass. JAMA Surg. 2015; 150(8): 787-94.
25. Stefater MA, Wilson-Pérez HE, Chambers AP, et al.: All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev. 2012; 33(4): 595-622.
26. Angrisani L, Santonicola A, Iovino P, et al.: Bariatric Surgery Worldwide 2013. Obes Surg. 2015; 25(10): 1822-32.
27. Yin DP, Gao Q, Ma LL, et al.: Assessment of different bariatric surgeries in the treatment of obesity and insulin resistance in mice. Ann Surg. 2011; 254(1): 73-82.
28. Yin DP, Boyd KL, Williams PE, et al.: Mouse Models of Bariatric Surgery. Curr Protoc Mouse Biol. 2012; 2012: pii: mo120087.
29. Masuda T, Ohta M, Hirashita T, et al.: A comparative study of gastric banding and sleeve gastrectomy in an obese diabetic rat model. Obes Surg. 2011; 21(11): 1774-80.
30. Kawasaki T, Ohta M, Kawano Y, et al.: Effects of sleeve gastrectomy and gastric banding on the hypothalamic feeding center in an obese rat model. Surg Today. 2015; 45(12): 1560-6.
31. Hirashita T, Ohta M, Endo Y, et al.: Effects of visceral fat resection and gastric banding in an obese diabetic rat model. Surgery. 2012; 151(1): 6-12.
32. Kohli R, Bradley D, Setchell KD, et al.: Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013; 98(4): E708-12.
33. Usinger L, Hansen KB, Kristiansen VB, et al.: Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding. Obes Surg. 2011; 21(5): 625-32.
34. Dixon JB, O'Brien PE, Playfair J, et al.: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008; 299(3): 316-23.
35. Frühbeck G, Rotellar F, Hernández-Lizoain JL, et al.: Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg. 2004; 14(9): 1208-15.
36. Genco A, López-Nava G, Wahlen C, et al.: Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience. Obes Surg. 2013; 23(4): 515-21.
37. Lopez-Nava G, Bautista-Castaño I, Jimenez-Baños A, et al.: Dual Intragastric Balloon: Single Ambulatory Center Spanish Experience with 60 Patients in Endoscopic Weight Loss Management. Obes Surg. 2015; 25(12): 2263-7.
38. Ponce J, Woodman G, Swain J, et al.: The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis. 2015; 11(4): 874-81.
39. Grayson BE, Schneider KM, Woods SC, et al.: Improved rodent maternal metabolism but reduced intrauterine growth after vertical sleeve gastrectomy. Sci Transl Med. 2013; 5(199): 199ra112.
40. National Research Council (US) Subcommittee on Laboratory Animal Nutrition: Nutrient Requirements of Laboratory Animals: Fourth Revised Edition, 1995. National Academies, 1995; 1.
41. Choi E, Roland JT, Barlow BJ, et al.: Cell lineage distribution atlas of the human stomach reveals heterogeneous gland populations in the gastric antrum. Gut. 2014; 63(11): 1711-20.
42. Karamanakos SN, Vagenas K, Kalfarentzos F, et al.: Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008; 247(3): 401-7.
43. Peterli R, Steinert RE, Woelnerhanssen B, et al.: Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012; 22(5): 740-8.
44. Papamargaritis D, Le Roux CW, Sioka E, et al.: Changes in gut hormone profile and glucose homeostasis after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2013; 9(2): 192-201.
45. Mallipedhi A, Prior SL, Barry JD, et al.: Temporal changes in glucose homeostasis and incretin hormone response at 1 and 6 months after laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2014; 10(5): 860-9.
46. Chambers AP, Kirchner H, Wilson-Perez HE, et al.: The effects of vertical sleeve gastrectomy in rodents are ghrelin independent. Gastroenterology. 2013; 144(1): 50-52.e5.
47. Wilson-Pérez HE, Chambers AP, Ryan KK, et al.: Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes. 2013; 62(7): 2380-5.
48. Ryan KK, Tremaroli V, Clemmensen C, et al.: FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014; 509(7499): 183-8.
49. Myronovych A, Kirby M, Ryan KK, et al.: Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner. Obesity (Silver Spring). 2014; 22(2): 390-400.
50. Belgaumkar AP, Vincent RP, Carswell KA, et al.: Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease. Obes Surg. 2016. 26(6): 1195-202.
51. Wilson-Pérez HE, Chambers AP, Sandoval DA, et al.: The effect of vertical sleeve gastrectomy on food choice in rats. Int J Obes (Lond). 2013; 37(2): 288-95.
52. le Roux CW, Bueter M, Theis N, et al.: Gastric bypass reduces fat intake and preference. Am J Physiol Regul Integr Comp Physiol. 2011; 301(4): R1057-66.
53. Chambers AP, Wilson-Perez HE, McGrath S, et al.: Effect of vertical sleeve gastrectomy on food selection and satiation in rats. Am J Physiol Endocrinol Metab. 2012; 303(8): E1076-84.
54. Stefater MA, Sandoval DA, Chambers AP, et al.: Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. Gastroenterology. 2011; 141(3): 939-949.e1-4.
55. Hammer HF: Medical complications of bariatric surgery: focus on malabsorption and dumping syndrome. Dig Dis. 2012; 30(2): 182-6.
56. Isom KA, Andromalos L, Ariagno M, et al.: Nutrition and metabolic support recommendations for the bariatric patient. Nutr Clin Pract. 2014; 29(6): 718-39.
57. Topart P, Becouarn G, Sallé A, et al.: Biliopancreatic diversion requires multiple vitamin and micronutrient adjustments within 2 years of surgery. Surg Obes Relat Dis. 2014; 10(5): 936-41.
58. Risstad H, Søvik TT, Engström M, et al.: Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. JAMA Surg. 2015; 150(4): 352-61.
59. Marceau P, Biron S, Marceau S, et al.: Biliopancreatic diversion-duodenal switch: independent contributions of sleeve resection and duodenal exclusion. Obes Surg. 2014; 24(11): 1843-9.
60. Meirelles K, Ahmed T, Culnan DM, et al.: Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg. 2009; 249(2): 277-85.
61. Mingrone G, Panunzi S, De Gaetano A, et al.: Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012; 366(17): 1577-85.
62. Astiarraga B, Gastaldelli A, Muscelli E, et al.: Biliopancreatic diversion in nonobese patients with type 2 diabetes: impact and mechanisms. J Clin Endocrinol Metab. 2013; 98(7): 2765-73.
63. Flynn CR, Albaugh VL, Cai S, et al.: Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat Commun. 2015; 6: 7715.
64. Li W, Baraboi ED, Cluny NL, et al.: Malabsorption plays a major role in the effects of the biliopancreatic diversion with duodenal switch on energy metabolism in rats. Surg Obes Relat Dis. 2015; 11(2): 356-66.
65. Scopinaro N, Adami GF, Marinari GM, et al.: Biliopancreatic diversion. World J Surg. 1998; 22(9): 936-46.
66. Carswell KA, Vincent RP, Belgaumkar AP, et al.: The effect of bariatric surgery on intestinal absorption and transit time. Obes Surg. 2014; 24(5): 796-805.
67. Odstrcil EA, Martinez JG, Santa Ana CA, et al.: The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr. 2010; 92(4): 704-13.
68. Wang G, Agenor K, Pizot J, et al.: Accelerated gastric emptying but no carbohydrate malabsorption 1 year after gastric bypass surgery (GBP). Obes Surg. 2012; 22(8): 1263-7.
69. Scopinaro N, Marinari GM, Pretolesi F, et al.: Energy and nitrogen absorption after biliopancreatic diversion. Obes Surg. 2000; 10(5): 436-41.
70. Stock-Damgé C, Aprahamian M, Raul F, et al.: Small-intestinal and colonic changes after biliopancreatic bypass for morbid obesity. Scand J Gastroenterol. 1986; 21(9): 1115-23.
71. Scopinaro N, Gianetta E, Adami GF, et al.: Biliopancreatic diversion for obesity at eighteen years. Surgery. 1996; 119(3): 261-8.
72. Pacheco D, de Luis DA, Romero A, et al.: The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg. 2007; 194(2): 221-4.
73. Rubino F, Marescaux J: Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004; 239(1): 1-11.
74. Hansen EN, Tamboli RA, Isbell JM, et al.: Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol Gastrointest Liver Physiol. 2011; 300(5): G795-802.
75. Pournaras DJ, Aasheim ET, Bueter M, et al.: Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss. Surg Obes Relat Dis. 2012; 8(4): 371-4.
76. Habegger KM, Al-Massadi O, Heppner KM, et al.: Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. Gut. 2014; 63(8): 1238-46.
77. Kindel TL, Martins PJ, Yoder SM, et al.: Bypassing the duodenum does not improve insulin resistance associated with diet-induced obesity in rodents. Obesity (Silver Spring). 2011; 19(2): 380-7.
78. Kindel TL, Yoder SM, Seeley RJ, et al.: Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptormediated mechanism. J Gastrointest Surg. 2009; 13(10): 1762-72.
79. Rubino F, Forgione A, Cummings DE, et al.: The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006; 244(5): 741-9.
80. Vetter ML, Wadden TA, Teff KL, et al.: GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification. Diabetes. 2015; 64(2): 434-46.
81. Spak E, Björklund P, Helander HF, et al.: Changes in the mucosa of the Roux-limb after gastric bypass surgery. Histopathology. 2010; 57(5): 680-8.
82. Saeidi N, Meoli L, Nestoridi E, et al.: Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science. 2013; 341(6144): 406-10.
83. Borg CM, le Roux CW, Ghatei MA, et al.: Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. Obes Surg. 2007; 17(9): 1193-8.
84. Rhee NA, Wahlgren CD, Pedersen J, et al.: Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia. 2015; 58(10): 2254-8.
85. le Roux CW, Borg C, Wallis K, et al.: Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg. 2010; 252(1): 50-6.
86. Pepino MY, Bradley D, Eagon JC, et al.: Changes in taste perception and eating behavior after bariatric surgery-induced weight loss in women. Obesity (Silver Spring). 2014; 22(5): E13-20.
87. Pepino MY, Stein RI, Eagon JC, et al.: Bariatric surgery-induced weight loss causes remission of food addiction in extreme obesity. Obesity (Silver Spring). 2014; 22(8): 1792-8.
88. Hajnal A, Kovacs P, Ahmed T, et al.: Gastric bypass surgery alters behavioral and neural taste functions for sweet taste in obese rats. Am J Physiol Gastrointest Liver Physiol. 2010; 299(4): G967-79.
89. Thanos PK, Subrize M, Delis F, et al.: Gastric bypass increases ethanol and water consumption in diet-induced obese rats. Obes Surg. 2012; 22(12): 1884-92.
90. Dunn JP, Cowan RL, Volkow ND, et al.: Decreased dopamine type 2 receptor availability after bariatric surgery: preliminary findings. Brain Res. 2010; 1350: 123-30.
91. Thanos PK, Michaelides M, Subrize M, et al.: Roux-en-Y Gastric Bypass Alters Brain Activity in Regions that Underlie Reward and Taste Perception. PLoS One. 2015; 10(6): e0125570.
92. Pal A, Rhoads DB, Tavakkoli A: Foregut exclusion disrupts intestinal glucose sensing and alters portal nutrient and hormonal milieu. Diabetes. 2015; 64(6): 1941-50.
93. Shin AC, Zheng H, Berthoud HR: Vagal innervation of the hepatic portal vein and liver is not necessary for Roux-en-Y gastric bypass surgery-induced hypophagia, weight loss, and hypermetabolism. Ann Surg. 2012; 255(2): 294-301.
94. Bhutta HY, Rajpal N, White W, et al.: Effect of Roux-en-Y gastric bypass surgery on bile acid metabolism in normal and obese diabetic rats. PLoS One. 2015; 10(3): e0122273.
95. Isbell JM, Tamboli RA, Hansen EN, et al.: The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care. 2010; 33(7): 1438-42.
96. Jackness C, Karmally W, Febres G, et al.: Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and β-cell Function in type 2 diabetic patients. Diabetes. 2013; 62(9): 3027-32.
97. Oliván B, Teixeira J, Bose M, et al.: Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg. 2009; 249(6): 948-53.
98. Dunn JP, Abumrad NN, Breitman I, et al.: Hepatic and peripheral insulin sensitivity and diabetes remission at 1 month after Roux-en-Y gastric bypass surgery in patients randomized to omentectomy. Diabetes Care. 2012; 35(1): 137-42.
99. Bojsen-Møller KN, Dirksen C, Jørgensen NB, et al.: Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014; 63(5): 1725-37.
100. Tamboli RA, Breitman I, Marks-Shulman PA, et al.: Early weight regain after gastric bypass does not affect insulin sensitivity but is associated with elevated ghrelin. Obesity (Silver Spring). 2014; 22(7): 1617-22.
101. Campos GM, Rabl C, Peeva S, et al.: Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg. 2010; 14(1): 15-23.
102. Nestoridi E, Kvas S, Kucharczyk J, et al.: Resting energy expenditure and energetic cost of feeding are augmented after Roux-en-Y gastric bypass in obese mice. Endocrinology. 2012; 153(5): 2234-44.
103. Stylopoulos N, Hoppin AG, Kaplan LM: Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring). 2009; 17(10): 1839-47.
104. Shin AC, Zheng H, Townsend RL, et al.: Longitudinal assessment of food intake, fecal energy loss, and energy expenditure after Roux-en-Y gastric bypass surgery in high-fat-fed obese rats. Obes Surg. 2013; 23(4): 531-40.
105. Kaiyala KJ: Mathematical model for the contribution of individual organs to non-zero y-intercepts in single and multi-compartment linear models of wholebody energy expenditure. PLoS One. 2014; 9(7): e103301.
106. Tschöp MH, Speakman JR, Arch JR, et al.: A guide to analysis of mouse energy metabolism. Nat Methods. 2011; 9(1): 57-63.
107. Butler AA, Kozak LP: A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes. Diabetes. 2010; 59(2): 323-9.
108. Schmidt JB, Pedersen SD, Gregersen NT, et al.: Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial. Int J Obes (Lond). 2016; 40(2): 281-90.
109. Tamboli RA, Hossain HA, Marks PA, et al.: Body composition and energy metabolism following Roux-en-Y gastric bypass surgery. Obesity (Silver Spring). 2010; 18(9): 1718-24.
110. Knuth ND, Johannsen DL, Tamboli RA, et al.: Metabolic adaptation following massive weight loss is related to the degree of energy imbalance and changes in circulating leptin. Obesity (Silver Spring). 2014; 22(12): 2563-9.
111. Adami GF, Compostano A, Bessarione D, et al.: Resting Energy Expenditure in Long-Term Postobese Subjects after Weight Normalization by Dieting or Biliopancreatic Diversion. Obes Surg. 1993; 3(4): 397-9.
112. Koopmans HS, Sclafani A, Fichtner C, et al.: The effects of ileal transposition on food intake and body weight loss in VMH-obese rats. Am J Clin Nutr. 1982; 35(2): 284-93.
113. Culnan DM, Albaugh V, Sun M, et al.: Ileal interposition improves glucose tolerance and insulin sensitivity in the obese Zucker rat. Am J Physiol Gastrointest Liver Physiol. 2010; 299(3): G751-60.
114. Cummings BP, Strader AD, Stanhope KL, et al.: Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology. 2010; 138(7): 2437-46, 2446.e1.
115. Strader AD, Vahl TP, Jandacek RJ, et al.: Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab. 2005; 288(2): E447-53.
116. Strader AD, Clausen TR, Goodin SZ, et al.: Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats. Obes Surg. 2009; 19(1): 96-104.
117. Ramzy AR, Nausheen S, Chelikani PK: Ileal transposition surgery produces ileal length-dependent changes in food intake, body weight, gut hormones and glucose metabolism in rats. Int J Obes (Lond). 2014; 38(3): 379-87.
118. Hansen CF, Vassiliadis E, Vrang N, et al.: The effect of ileal interposition surgery on enteroendocrine cell numbers in the UC Davis type 2 diabetes mellitus rat. Regul Pept. 2014; 189: 31-9.
119. Tam CS, Berthoud HR, Bueter M, et al.: Could the mechanisms of bariatric surgery hold the key for novel therapies? report from a Pennington Scientific Symposium. Obes Rev. 2011; 12(11): 984-94.
120. Keig HE, Belmonte RL Jr, McKain JM, et al.: The effect of bile diversion on induced hypercholesterolemia. Arch Surg. 1968; 96(4): 613-8.
121. Morgan CV Jr, Lanier VC, Finch WT, et al.: Protective effects of bile diversion to the distal fourth of small intestine against experimental hypercholesterolemia and atherosclerosis in dogs. Am Surg. 1972; 38(1): 10-2.
122. Buchwald H, Gebhard RL: Effect of Intestinal Bypass on Cholesterol Absorption and Blood Levels in the Rabbit. Am J Physiol. 1964; 207: 567-72.
123. Scott HW Jr, Stephenson SE Jr, Younger R, et al.: Prevention of experimental atherosclerosis by ileal bypass: 20 per cent cholesterol diet and I-131 induced hypothyroidism in dogs. Ann Surg. 1966; 163(5): 795-807.
124. Buchwald H, Varco RL, Matts JP, et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990; 323(14): 946-55.
125. Thomas C, Gioiello A, Noriega L, et al.: TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009; 10(3): 167-77.
126. Lefebvre P, Cariou B, Lien F, et al.: Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009; 89(1): 147-91.
127. Leriche R, Joung A: Essai sur le traitement chirurgical du diabete par la derivation biliaire: documents experimentaux et cliniques. Annales dEndocrinologie. 1939; 1: 3-10.
128. Manfredini G, Ermini M, Scopsi L, et al.: Internal biliary diversion improves glucose tolerance in the rat. Am J Physiol. 1985; 249(4 Pt 1): G519-27.
129. Goncalves D, Barataud A, De Vadder F, et al.: Bile Routing Modification Reproduces Key Features of Gastric Bypass in Rat. Ann Surg. 2015; 262(6): 1006-15.
130. Kohli R, Setchell KD, Kirby M, et al.: A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. Endocrinology. 2013; 154(7): 2341-51.
131. Kohli R, Kirby M, Setchell KD, et al.: Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol. 2010; 299(3): G652-60.
132. Sayin SI, Wahlström A, Felin J, et al.: Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2): 225-35.
133. Albaugh VL, Flynn CR, Cai S, et al.: Early Increases in Bile Acids Post Roux-en-Y Gastric Bypass Are Driven by Insulin-Sensitizing, Secondary Bile Acids. J Clin Endocrinol Metab. 2015; 100(9): E1225-33.
134. Steinert RE, Peterli R, Keller S, et al.: Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity (Silver Spring). 2013; 21(12): E660-8.
135. Werling M, Vincent RP, Cross GF, et al.: Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol. 2013; 48(11): 1257-64.
136. Patti ME, Houten SM, Bianco AC, et al.: Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009; 17(9): 1671-7.
137. Dutia R, Embrey M, O'Brien S, et al.: Temporal changes in bile acid levels and 12a-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes (Lond). 2015; 39(5): 806-13.
138. Ferrannini E, Camastra S, Astiarraga B, et al.: Increased Bile Acid Synthesis and Deconjugation After Biliopancreatic Diversion. Diabetes. 2015; 64(10): 3377-85.
139. Ryan KK, Kohli R, Gutierrez-Aguilar R, et al.: Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology. 2013; 154(1): 9-15.
140. Pournaras DJ, Glicksman C, Vincent RP, et al.: The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012; 153(8): 3613-9.
141. Gerhard GS, Styer AM, Wood GC, et al.: A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013; 36(7): 1859-64.
142. Jørgensen NB, Dirksen C, Bojsen-Møller KN, et al.: Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J Clin Endocrinol Metab. 2015; 100(3): E396-406.
143. Li S, Hsu DD, Li B, et al.: Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab. 2014; 20(2): 320-32.
144. Düfer M, Hörth K, Wagner R, et al.: Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and KATP channel inhibition. Diabetes. 2012; 61(6): 1479-89.
145. Trabelsi MS, Daoudi M, Prawitt J, et al.: Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun. 2015; 6: 7629.
146. Bäckhed F, Ding H, Wang T, et al.: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004; 101(44): 15718-23.
147. Liou AP, Paziuk M, Luevano JM Jr, et al.: Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013; 5(178): 178ra41.
148. Tremaroli V, Karlsson F, Werling M, et al.: Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. Cell Metab. 2015; 22(2): 228-38.
149. Chen Z, Guo L, Zhang Y, et al.: Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J Clin Invest. 2014; 124(8): 3391-406.
150. Vidal J, Jiménez A, de Hollanda A, et al.: Metabolic Surgery in Type 2 Diabetes: Roux-en-Y Gastric Bypass or Sleeve Gastrectomy as Procedure of Choice? Curr Atheroscler Rep. 2015; 17(10): 58.